ZBIO
NASDAQZenas BioPharma Inc.
Price$18.50+0.41 (+2.27%)
01:30 PM07:45 PM
News · 26 weeks53-17%
2025-12-142026-06-07
Mix3490d
- SEC Filings15(44%)
- Other12(35%)
- Insider6(18%)
- Offering1(3%)
Latest news
25 items- PRZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related toxicities - - A Biologics License Application (BLA) for obexelimab in IgG4-RD was submitted to the FDA in May - WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the presentation of add
- PRZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often resulting in irreversi
- PRZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that safety and efficacy outcomes from the Phase 3 INDIGO trial evaluating obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) will be presented in an oral presentation at the upcoming European
- INSIDERChief Executive Officer Moulder Leon O Jr bought $1,012,800 worth of shares (60,000 units at $16.88) (SEC Form 4)4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- PRZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on May 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted an aggregate of 51,075 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the
- PRZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - - Phase 1 SAD and MAD data expected by year-end 2026, with proof-of-concept data in psoriasis patients anticipated in 2027 - WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that the first subject has been dosed in the Phase 1 t
- SECSEC Form 10-Q filed by Zenas BioPharma Inc.10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)
- SECZenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Zenas BioPharma, Inc. (0001953926) (Filer)
- PRZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – – Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 – – Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 – – First subject dosed in Phase 1 trial of ZB021 (oral IL-17AA/AF inhibitor); initial clinical data expected by year-end – – Orelabrutinib global Phase 3 PriMroSe trial in patients with PPMS and global Phase 3 Monarch trial in patients with naSPMS ongoing – – Completed public offerings and entered into
- SECSEC Form SCHEDULE 13D filed by Zenas BioPharma Inc.SCHEDULE 13D - Zenas BioPharma, Inc. (0001953926) (Subject)
- INSIDERChief Executive Officer Moulder Leon O Jr bought $1,067,200 worth of shares (60,000 units at $17.79) (SEC Form 4)4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- PRZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on April 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted an aggregate of 41,475 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Zenas BioPharma Inc.SCHEDULE 13D/A - Zenas BioPharma, Inc. (0001953926) (Subject)
- INSIDERSEC Form 4 filed by Lu Hongbo4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- INSIDERSEC Form 4 filed by Fairmount Funds Management Llc4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- INSIDERSEC Form 4 filed by Moulder Leon O Jr4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- INSIDERSEC Form 4 filed by Lu Hongbo4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
- SECZenas BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Zenas BioPharma, Inc. (0001953926) (Filer)
- SECSEC Form 424B5 filed by Zenas BioPharma Inc.424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
- SECSEC Form 424B5 filed by Zenas BioPharma Inc.424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
- SECSEC Form FWP filed by Zenas BioPharma Inc.FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
- SECSEC Form FWP filed by Zenas BioPharma Inc.FWP - Zenas BioPharma, Inc. (0001953926) (Subject)
- PRZenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionWALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offerin
- SECSEC Form 424B5 filed by Zenas BioPharma Inc.424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
- SECSEC Form 424B5 filed by Zenas BioPharma Inc.424B5 - Zenas BioPharma, Inc. (0001953926) (Filer)
ZBIO FAQ
6 questionsWhere does ZBIO stock trade?
Zenas BioPharma Inc. (ZBIO) is listed on NASDAQ.What sector and industry is ZBIO in?
Zenas BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zenas BioPharma Inc. go public?
Zenas BioPharma Inc. (ZBIO) completed its IPO in 2024.What are analysts saying about ZBIO?
Zenas BioPharma Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $1900.00 price target on 2026-01-05. Recent price targets range from $1900.00 to $4500.00.What companies are similar to ZBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZBIO side-by-side with any of them on Quantisnow.How can I track ZBIO on Quantisnow?
Quantisnow aggregates Zenas BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZBIO to receive live email and push alerts on every new disclosure.